valproic acid has been researched along with Depressive Disorder in 103 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An epileptic patient well controlled on valproic acid (VPA) developed a prolonged episode of status epilepticus 12 days after initiation of 75 mg of clomipramine (CMI) to treat depression." | 7.69 | Status epilepticus associated with the combination of valproic acid and clomipramine. ( DeToledo, JC; Haddad, H; Ramsay, RE, 1997) |
| "Aripiprazole is an atypical antipsychotic compound that is approved by the U." | 6.73 | Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. ( Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M, 2008) |
| ", who received at least 6 weeks of add-on olanzapine treatment for psychotic mood disorders (schizoaffective disorders [bipolar and depressive type], bipolar disorders [I, II, and NOS], and major depressive disorder)." | 5.09 | Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. ( Grace, JJ; Narendran, R; Pato, MT; Pristach, CA; Valenti, AM; Young, CM, 2001) |
| "Bupropion (BUP) may be less likely than other antidepressants to cause switches into mania and rapid cycling, suggesting utility in bipolar disorder." | 5.08 | Carbamazepine but not valproate induces bupropion metabolism. ( Callahan, AM; Chao, J; George, MS; Hinton, ML; Jenkins, JB; Ketter, TA; Marangell, LB; Pazzaglia, PJ; Post, RM; Schroeder, DH, 1995) |
| "Thirty-five patients, all with major depressive illness, bipolar disorder, or schizoaffective disorder, were retrospectively identified as having received valproate either alone or in combination with lithium, after having failed to adequately respond to previous lithium and/or carbamazepine treatment." | 5.06 | Long-term use of valproate in primary psychiatric disorders. ( Hayes, SG, 1989) |
| "Although monotherapy with lithium or divalproex is the recommended initial therapy for bipolar disorder, these agents are associated with prolonged favorable outcomes in only 30% of patients." | 4.82 | Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. ( Bowden, CL, 2005) |
| "Mood-stabilizing drugs including lithium, anticonvulsants, and antipsychotics have established effects in the management of bipolar disorder, especially in mania." | 4.80 | Mood-stabilizing drugs in depression. ( Shelton, RC, 1999) |
| "The present study aimed to develop a neurochemistry-based single or adjuvant therapy approach for comprehensive management of epilepsy and associated depression employing pentylenetetrazole-kindled animals." | 3.83 | Evidence in support of using a neurochemistry approach to identify therapy for both epilepsy and associated depression. ( Goel, RK; Singh, T, 2016) |
| "To study the effectiveness of adding lamotrigine to the treatment of inpatient geriatric patients with bipolar disorder (BD) who were in the depressed phase and had been on lithium and valproate for at least 3 months." | 3.71 | Lamotrigine use in geriatric patients with bipolar depression. ( Conn, DK; Robillard, M, 2002) |
| "The purpose of this study was to determine the occurrence of leukopenia and other blood dyscrasias associated with psychiatric use of carbamazepine and valproate." | 3.69 | Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. ( Baldessarini, RJ; Castillo, J; Kando, JC; Tohen, M; Zarate, C, 1995) |
| "An epileptic patient well controlled on valproic acid (VPA) developed a prolonged episode of status epilepticus 12 days after initiation of 75 mg of clomipramine (CMI) to treat depression." | 3.69 | Status epilepticus associated with the combination of valproic acid and clomipramine. ( DeToledo, JC; Haddad, H; Ramsay, RE, 1997) |
| "Characterization of dose-response relationships for psychotropic agents may be difficult to determine based on results of individual clinical studies, particularly those with a flexible dose design." | 2.82 | Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. ( Chapel, S; Chiu, YY; Cucchiaro, J; Hsu, J; Loebel, A, 2016) |
| "Aripiprazole is an atypical antipsychotic compound that is approved by the U." | 2.73 | Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. ( Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M, 2008) |
| "To evaluate the efficacy of olanzapine, in combination with lithium or valproate, for treating depressive symptoms associated with mania." | 2.71 | Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. ( Akiskal, HS; Baker, RW; Brown, E; Calabrese, JR; Ketter, TA; Schuh, LM; Tohen, M; Trzepacz, PT; Watkin, JG, 2004) |
| "Borderline personality disorder is characterized by affective instability, impulsivity, and aggression and is associated with considerable morbidity and mortality." | 2.70 | A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. ( Allen, A; Bienstock, CA; Grossman, R; Hollander, E; Lopez, RP; Merkatz, L; Siever, LJ; Stein, DJ, 2001) |
| "Substance abuse is a common comorbid illness in patients with mood disorders." | 2.69 | Divalproex sodium in substance abusers with mood disorder. ( Albanese, MJ; Clodfelter, RC; Khantzian, EJ, 2000) |
| "A major challenge in the treatment of bipolar depression is the tendency for antidepressant medications, particularly tricyclic antidepressants, to precipitate episodes of mania, or to increase cycle frequency or symptom intensity." | 2.44 | The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders. ( Bourin, M; Prica, C, 2007) |
| "Although the treatment of bipolar depression remains an understudied area, new data from randomized, controlled trials and naturalistic studies have expanded the range of treatments available." | 2.42 | Bipolar depression: an overview. ( Oral, ET; Vahip, S, 2004) |
| "The rate of severe PD-related hair loss was very low in the present survey." | 1.48 | Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries. ( Bleich, S; Burda, K; Druschky, K; Frieling, H; Grohmann, R; Hillemacher, T; Neyazi, A; Stübner, S; Toto, S, 2018) |
| "Many types of medicaments can cause akathisia as an adverse event of their use and they include: antipsychotics, antidepressants, antiemetics, antihistamines, and psychoactive substances." | 1.37 | Symptoms of agitated depression and/or akathisia. ( Blažević-Zelić, S; Peitl, MV; Peitl, V; Prološčić, J; Skarpa-Usmiani, I, 2011) |
| " There have been no previous studies designed to investigate a potential pharmacokinetic (PK) interaction between MCB and VPA or CBZ; however, these agents are likely to be used concomitantly for the treatment of depressive disorders." | 1.35 | Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ( Miljkovic, B; Pokrajac, M; Rakic Ignjatovic, A; Timotijevic, I; Todorovic, D, 2009) |
| "One patient had moderate confusion, and the other mild confusion and hypomania." | 1.30 | Combined valproate or carbamazepine and electroconvulsive therapy. ( Baraibar, G; Tohen, M; Zarate, CA, 1997) |
| " Safety is increased through temporary discontinuation or dosage reduction of lithium in special risk situations." | 1.27 | New developments in long-term preventive therapy. ( Schou, M, 1986) |
| "These four patients had endogenous depression, and also an abnormal response to SV." | 1.27 | The effect of sodium valproate on serum cortisol levels in healthy subjects and depressed patients. ( Aggernaes, H; Kirkegaard, C; Magelund, G, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (11.65) | 18.7374 |
| 1990's | 32 (31.07) | 18.2507 |
| 2000's | 42 (40.78) | 29.6817 |
| 2010's | 16 (15.53) | 24.3611 |
| 2020's | 1 (0.97) | 2.80 |
| Authors | Studies |
|---|---|
| Esposito, M | 1 |
| Giunta, A | 1 |
| Del Duca, E | 1 |
| Manfreda, V | 1 |
| Troisi, A | 1 |
| Bianchi, L | 1 |
| Fargnoli, MC | 1 |
| Silva, EF | 1 |
| Silva, AI | 1 |
| Asth, L | 1 |
| Souza, LS | 1 |
| Zaveri, NT | 1 |
| Guerrini, R | 1 |
| Calo', G | 1 |
| Ruzza, C | 1 |
| Gavioli, EC | 1 |
| Druschky, K | 1 |
| Bleich, S | 1 |
| Grohmann, R | 1 |
| Burda, K | 1 |
| Frieling, H | 1 |
| Hillemacher, T | 1 |
| Neyazi, A | 1 |
| Stübner, S | 1 |
| Toto, S | 1 |
| Qiu, HM | 2 |
| Yang, JX | 2 |
| Liu, D | 2 |
| Fei, HZ | 2 |
| Hu, XY | 2 |
| Zhou, QX | 2 |
| Santos-Cubiñá, J | 1 |
| Torres-Rodríguez, A | 1 |
| Castaing-Lespier, PA | 1 |
| Sabaté, N | 1 |
| Torres-Martin, A | 1 |
| Carlo, S | 1 |
| San Miguel López de Uralde, SM | 1 |
| Prieto Peraita, M | 1 |
| Blanco Bengoechea, EJ | 1 |
| Jiang, XH | 1 |
| Sencion Martinez, GL | 1 |
| Samillán, K | 1 |
| Espinosa, JL | 1 |
| Rodriguez Puyol, D | 1 |
| Martinez Miguel, P | 1 |
| Villa, P | 1 |
| Chapel, S | 1 |
| Chiu, YY | 1 |
| Hsu, J | 1 |
| Cucchiaro, J | 1 |
| Loebel, A | 1 |
| Shansis, FM | 1 |
| Reche, M | 1 |
| Capp, E | 1 |
| Singh, T | 1 |
| Goel, RK | 1 |
| Pearlstein, T | 1 |
| Sümegi, A | 1 |
| Kacalak-Rzepka, A | 1 |
| Kiedrowicz, M | 1 |
| Bielecka-Grzela, S | 1 |
| Ratajczak-Stefanska, V | 1 |
| Maleszka, R | 1 |
| Mikulska, D | 1 |
| Bini, P | 1 |
| Montalbetti, L | 1 |
| Tosca, P | 1 |
| Ratti, MT | 1 |
| Uggetti, C | 1 |
| Moglia, A | 1 |
| Costa, A | 1 |
| Rakic Ignjatovic, A | 1 |
| Miljkovic, B | 1 |
| Todorovic, D | 1 |
| Timotijevic, I | 1 |
| Pokrajac, M | 1 |
| Wu, SW | 1 |
| Chang, HR | 1 |
| Lai, YR | 1 |
| Lian, JD | 1 |
| Praharaj, SK | 1 |
| Jana, AK | 1 |
| Sinha, VK | 1 |
| Deras, P | 1 |
| Gignon, L | 1 |
| Toumi, M | 1 |
| Louart, G | 1 |
| Muller, L | 1 |
| Boyer, JC | 1 |
| Lefrant, JY | 1 |
| Sajatovic, M | 2 |
| Al Jurdi, R | 1 |
| Gildengers, A | 1 |
| Greenberg, RL | 1 |
| Tenhave, T | 1 |
| Bruce, ML | 1 |
| Mulsant, B | 1 |
| Young, RC | 1 |
| Peitl, MV | 1 |
| Prološčić, J | 1 |
| Blažević-Zelić, S | 1 |
| Skarpa-Usmiani, I | 1 |
| Peitl, V | 1 |
| Liu, HY | 1 |
| Potter, MP | 1 |
| Woodworth, KY | 1 |
| Yorks, DM | 1 |
| Petty, CR | 1 |
| Wozniak, JR | 1 |
| Faraone, SV | 1 |
| Biederman, J | 1 |
| Singh, V | 1 |
| Bowden, CL | 4 |
| Mintz, J | 1 |
| Diler, RS | 1 |
| Ladouceur, CD | 1 |
| Segreti, A | 1 |
| Almeida, JR | 1 |
| Birmaher, B | 1 |
| Axelson, DA | 1 |
| Phillips, ML | 1 |
| Pan, LA | 1 |
| Jain, V | 1 |
| Swartz, CM | 1 |
| Robillard, M | 1 |
| Conn, DK | 1 |
| Raja, M | 1 |
| Azzoni, A | 1 |
| Post, RM | 3 |
| Leverich, GS | 1 |
| Nolen, WA | 1 |
| Kupka, RW | 1 |
| Altshuler, LL | 1 |
| Frye, MA | 1 |
| Suppes, T | 2 |
| McElroy, S | 1 |
| Keck, P | 1 |
| Grunze, H | 2 |
| Walden, J | 1 |
| Henry, CA | 1 |
| Zamvil, LS | 1 |
| Lam, C | 1 |
| Rosenquist, KJ | 1 |
| Ghaemi, SN | 1 |
| Keck, PE | 2 |
| McElroy, SL | 2 |
| Oral, ET | 1 |
| Vahip, S | 1 |
| Prapotnik, M | 1 |
| Di Pauli, J | 1 |
| Vetter, Z | 1 |
| König, P | 1 |
| Conca, A | 1 |
| Waschgler, R | 1 |
| Baker, RW | 1 |
| Brown, E | 1 |
| Akiskal, HS | 1 |
| Calabrese, JR | 5 |
| Ketter, TA | 2 |
| Schuh, LM | 1 |
| Trzepacz, PT | 1 |
| Watkin, JG | 1 |
| Tohen, M | 4 |
| Bauer, MS | 1 |
| Gajwani, P | 1 |
| Forsthoff, A | 1 |
| Muzina, D | 1 |
| Amann, B | 1 |
| Gao, K | 1 |
| Elhaj, O | 1 |
| Howland, RH | 1 |
| Bebarta, VS | 1 |
| Kostic, MA | 1 |
| Gonzalez, MG | 1 |
| Krüger, S | 1 |
| Alda, M | 1 |
| Young, LT | 1 |
| Goldapple, K | 1 |
| Parikh, S | 1 |
| Mayberg, HS | 1 |
| de Araujo Filho, GM | 1 |
| Pascalicchio, TF | 1 |
| Lin, K | 1 |
| Sousa, PS | 1 |
| Yacubian, EM | 1 |
| Thase, ME | 1 |
| Bajbouj, M | 1 |
| Gallinat, J | 2 |
| Lang, UE | 1 |
| Hellen, F | 1 |
| Vesper, J | 1 |
| Lisanby, SH | 1 |
| Danker-Hopfe, H | 1 |
| Neu, P | 1 |
| Bourin, M | 1 |
| Prica, C | 1 |
| Malatynska, E | 1 |
| Pinhasov, A | 1 |
| Crooke, JJ | 1 |
| Smith-Swintosky, VL | 1 |
| Brenneman, DE | 1 |
| Guelfi, JD | 1 |
| Perdrizet-Chevallier, C | 1 |
| Svestka, J | 1 |
| Rysánek, R | 1 |
| Cesková, E | 1 |
| Coconcea, N | 1 |
| Ignacio, RV | 1 |
| Blow, FC | 1 |
| Hays, RW | 1 |
| Cassidy, KA | 1 |
| Meyer, WJ | 1 |
| Emrich, HM | 2 |
| Günther, R | 1 |
| Dose, M | 1 |
| Uhde, TW | 1 |
| Puryear, LJ | 1 |
| Kunik, ME | 1 |
| Molinari, V | 1 |
| Workman, RH | 1 |
| Cruz-Flores, S | 1 |
| Hayat, GR | 1 |
| Mirza, W | 1 |
| Castillo, J | 2 |
| Baldessarini, RJ | 1 |
| Zarate, C | 1 |
| Kando, JC | 2 |
| Brady, KT | 1 |
| Sonne, S | 1 |
| Lydiard, RB | 1 |
| Schaff, MR | 1 |
| Fawcett, J | 1 |
| Zajecka, JM | 1 |
| Maes, M | 1 |
| Goossens, F | 1 |
| Scharpé, S | 1 |
| Calabrese, J | 1 |
| Desnyder, R | 1 |
| Meltzer, HY | 1 |
| Zarate, CA | 2 |
| Jenkins, JB | 1 |
| Schroeder, DH | 1 |
| Pazzaglia, PJ | 1 |
| Marangell, LB | 1 |
| George, MS | 1 |
| Callahan, AM | 1 |
| Hinton, ML | 1 |
| Chao, J | 1 |
| Davis, LL | 1 |
| Kabel, D | 1 |
| Patel, D | 1 |
| Choate, AD | 1 |
| Foslien-Nash, C | 1 |
| Gurguis, GN | 1 |
| Kramer, GL | 1 |
| Petty, F | 1 |
| DeToledo, JC | 1 |
| Haddad, H | 1 |
| Ramsay, RE | 1 |
| Baraibar, G | 1 |
| Raby, WN | 1 |
| Kusumakar, V | 1 |
| Yatham, LN | 1 |
| Baetz, M | 1 |
| Bowen, RC | 1 |
| Lucena, MI | 1 |
| Blanco, E | 1 |
| Corrales, MA | 1 |
| Berthier, ML | 1 |
| Dietrich, DE | 1 |
| Woods, SW | 1 |
| Dardennes, R | 1 |
| Even, C | 1 |
| Shelton, RC | 1 |
| Schatzberg, AF | 1 |
| DeBattista, C | 1 |
| Droulers, A | 1 |
| Bodak, N | 1 |
| Oudjhani, M | 1 |
| Lefevre des Noettes, V | 1 |
| Bodak, A | 1 |
| Juckel, G | 2 |
| Hegerl, U | 2 |
| Mavrogiorgou, P | 1 |
| Mager, T | 1 |
| Tigges, P | 2 |
| Dresel, S | 1 |
| Schröter, A | 2 |
| Stotz, G | 1 |
| Meller, I | 1 |
| Greil, W | 1 |
| Möller, HJ | 3 |
| Cassimatis, N | 1 |
| Albanese, MJ | 1 |
| Clodfelter, RC | 1 |
| Khantzian, EJ | 1 |
| Bottlender, R | 1 |
| Rudolf, D | 1 |
| Strauss, A | 1 |
| Hollander, E | 1 |
| Allen, A | 1 |
| Lopez, RP | 1 |
| Bienstock, CA | 1 |
| Grossman, R | 1 |
| Siever, LJ | 1 |
| Merkatz, L | 1 |
| Stein, DJ | 1 |
| Shelton, MD | 1 |
| Rapport, DJ | 1 |
| Shirley, ER | 1 |
| Kimmel, SE | 1 |
| Caban, SJ | 1 |
| Narendran, R | 1 |
| Young, CM | 1 |
| Valenti, AM | 1 |
| Pristach, CA | 1 |
| Pato, MT | 1 |
| Grace, JJ | 1 |
| Scott, J | 1 |
| Pope, M | 1 |
| Frankenburg, FR | 1 |
| Zanarini, MC | 1 |
| Villeneuve, A | 1 |
| Uehlinger, C | 1 |
| Barrelet, L | 1 |
| Touabi, M | 1 |
| Baumann, P | 1 |
| Corrigan, FM | 1 |
| Kemp, LI | 1 |
| Mitchell, P | 1 |
| Cullen, MJ | 1 |
| Delucchi, GA | 1 |
| Coplan, JD | 1 |
| Gorman, JM | 1 |
| Schneier, HA | 1 |
| Kahn, D | 1 |
| Brown, R | 1 |
| Hayes, SG | 1 |
| Pies, R | 1 |
| Adler, DA | 1 |
| Ehrenberg, BL | 1 |
| Cookson, JC | 1 |
| Pope, HG | 1 |
| Hudson, JI | 1 |
| Schou, M | 2 |
| Aggernaes, H | 1 |
| Kirkegaard, C | 1 |
| Magelund, G | 1 |
| Zapletálek, M | 1 |
| Hanus, H | 1 |
| Kindernayová, H | 1 |
| Vandel, S | 1 |
| Bertschy, G | 1 |
| Jounet, JM | 1 |
| Allers, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression[NCT00868699] | Phase 3 | 505 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Randomized, 6-Week, Double-Blind, Placebo- Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression[NCT00868452] | Phase 3 | 348 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Homeopathic Treatment in Pregnant Women With Overweight and Mental Disorder: a Double Blinded Controlled Clinical Trial[NCT00942097] | Phase 2/Phase 3 | 134 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Acute Pharmacotherapy of Late-Life Mania (GERI-BD)[NCT00254488] | Phase 4 | 224 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972] | Phase 2 | 16 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants) | ||
| Aripiprazole in Late Life Bipolar Disorder[NCT00194038] | Phase 4 | 20 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression.~The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.~The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items." (NCT00868699)
Timeframe: Baseline to Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -10.7 |
| Lurasidone High Arm | -15.4 |
| Lurasidone Low Arm | -15.4 |
"Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression.~The CGI depression score ranges from a minimum of 0 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome." (NCT00868699)
Timeframe: Baseline to Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.14 |
| Lurasidone High Arm | -1.71 |
| Lurasidone Low Arm | -1.83 |
"Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of depression.~The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.~The SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items." (NCT00868699)
Timeframe: Baseline to Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -6.3 |
| Lurasidone High Arm | -9.8 |
| Lurasidone Low Arm | -9.5 |
MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening. (NCT00868452)
Timeframe: Baseline, Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lurasidone | -17.1 |
| Placebo | -13.5 |
CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening. (NCT00868452)
Timeframe: Baseline Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lurasidone | -1.96 |
| Placebo | -1.51 |
STS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening. (NCT00868452)
Timeframe: Baselin Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lurasidone | -9.5 |
| Placebo | -7.0 |
The Sedation Item score of the UKU (Norwegian for Committee of Clinical Investigations) Side Effect Rating Scale. A higher value indicates greater severity. Range is 0-3 (not present, mild, moderate, or severe). (NCT00254488)
Timeframe: Day 4, Day 9, Day 15, and then Weekly from Week 3 to Week 9
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 4 | Day 9 | Day 15 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | |
| Divalproex (DV) | 0.5 | 0.6 | 0.5 | 0.6 | 0.5 | 0.4 | 0.5 | 0.4 | 0.3 | 0.4 |
| Lithium (LI) | 0.5 | 0.6 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 |
The Young Mania Rating Scale is an eleven item interviewer-rated instrument. Four items are scored 0-8, the others 0-4. The total score therefore ranges from 0-60, with higher values reflecting greater severity. (NCT00254488)
Timeframe: Day 4, Day 9, Day 15, and then Weekly from Week 3 to Week 9
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 4 | Day 9 | Day 15 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | |
| Divalproex (DV) | 19.7 | 16.3 | 15.2 | 13.1 | 9.9 | 9.8 | 8.2 | 7.0 | 6.7 | 6.8 |
| Lithium (LI) | 21.4 | 19.0 | 14.3 | 12.1 | 9.4 | 7.6 | 7.2 | 6.0 | 6.0 | 6.3 |
25 reviews available for valproic acid and Depressive Disorder
| Article | Year |
|---|---|
Perinatal depression: treatment options and dilemmas.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Case-Control Studies; Cyclohexan | 2008 |
[Mood stabilizers--past, present and future].
Topics: Affect; Antimanic Agents; Bipolar Disorder; Calcium; Carbamazepine; Depressive Disorder; gamma-Amino | 2008 |
Rowell's syndrome in the course of treatment with sodium valproate: a case report and review of the literature data.
Topics: Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Drug Therapy, Combination; Erythema Mult | 2009 |
Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivi | 2011 |
A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network.
Topics: Adult; Affect; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Dr | 2003 |
Divalproex in the treatment of bipolar disorder.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Humans; Valproic Acid | 2003 |
Bipolar depression: an overview.
Topics: Acute Disease; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Chemoprev | 2004 |
Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; De | 2005 |
Antiepileptic drugs in mood-disordered patients.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Depressive Disorder; Humans; Lamotrigine; Treatmen | 2005 |
Anticonvulsant drug therapies.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Depressive Di | 2005 |
Managing adverse reactions to psychotropic medications.
Topics: Adolescent; Anticonvulsants; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivit | 2005 |
Bipolar depression: diagnostic and treatment considerations.
Topics: Age of Onset; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Child; Depressive Disor | 2006 |
The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders.
Topics: Affective Symptoms; Animals; Antimanic Agents; Bipolar Disorder; Carbamazepine; Depressive Disorder; | 2007 |
Current perspectives in the pharmacopsychiatry of depression and mania.
Topics: Affective Disorders, Psychotic; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Endorp | 1983 |
Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Clonazepam; Depressive D | 1983 |
Treatment guidelines for valproate in bipolar and schizoaffective disorders.
Topics: Bipolar Disorder; Depressive Disorder; Drug Monitoring; Humans; Metabolic Clearance Rate; Psychotic | 1993 |
The use of anticonvulsants to augment antidepressant medication.
Topics: Adult; Ambulatory Care; Amitriptyline; Anticonvulsants; Antidepressive Agents; Carbamazepine; Clinic | 1998 |
[Current trends in the therapeutic use of thymic regulators].
Topics: Anticonvulsants; Antidepressive Agents; Depressive Disorder; Female; Humans; Lithium; Mood Disorders | 1998 |
Mood-stabilizing drugs in depression.
Topics: Acute Disease; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Diso | 1999 |
Phenomenology and treatment of agitation.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 1999 |
Bipolar rapid cycling: focus on depression as its hallmark.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Bipolar Disorder; Comorbidity; Controlled Clinica | 2001 |
Treatment of anxiety disorder in patients with mood disorders.
Topics: Antidepressive Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Depressive Disorder; Humans; L | 1990 |
U.S. experience with valproate in manic depressive illness: a multicenter trial.
Topics: Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Humans; Middle Aged; P | 1989 |
Drug treatment of bipolar depression and mania.
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Bromocriptine; Carbamazepine; Choline | 1985 |
Antidepressant drug therapy for bulimia: current status.
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method | 1986 |
21 trials available for valproic acid and Depressive Disorder
| Article | Year |
|---|---|
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Computer Simulation; Depressive Dis | 2016 |
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Computer Simulation; Depressive Dis | 2016 |
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Computer Simulation; Depressive Dis | 2016 |
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Computer Simulation; Depressive Dis | 2016 |
Evaluating response to mood stabilizers in patients with mixed depression: A study of agreement between three different mania rating scales and a depression rating scale.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Depressive Disorder; Diagnostic and Statis | 2016 |
Depression symptom ratings in geriatric patients with bipolar mania.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Metho | 2011 |
Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Diagnostic an | 2013 |
Long-term outcome with divalproex in children and adolescents with bipolar disorder.
Topics: Adolescent; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; | 2003 |
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorde | 2004 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Ther | 2007 |
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data.
Topics: Acetamides; Adult; Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Female; Humans; Li | 2007 |
Treatment of endogenous depressions with valpromide (open study).
Topics: Adult; Aged; Anticonvulsants; Antimanic Agents; Depressive Disorder; Female; Humans; Male; Middle Ag | 1991 |
Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorde | 2008 |
Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Clonazepam; Depressive D | 1983 |
Carbamazepine but not valproate induces bupropion metabolism.
Topics: Adult; Antidepressive Agents; Biotransformation; Bipolar Disorder; Bupropion; Carbamazepine; Cytochr | 1995 |
Valproate as an antidepressant in major depressive disorder.
Topics: Adult; Aged; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatri | 1996 |
Divalproex sodium in substance abusers with mood disorder.
Topics: Adult; Anticonvulsants; Behavior, Addictive; Bipolar Disorder; Comorbidity; Depressive Disorder; Dru | 2000 |
A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.
Topics: Adolescent; Adult; Aggression; Ambulatory Care; Anticonvulsants; Borderline Personality Disorder; Co | 2001 |
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.
Topics: Adult; Affective Disorders, Psychotic; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; | 2001 |
Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.
Topics: Adult; Aggression; Anger; Anticonvulsants; Bipolar Disorder; Borderline Personality Disorder; Comorb | 2002 |
Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Depressive | 1990 |
U.S. experience with valproate in manic depressive illness: a multicenter trial.
Topics: Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Humans; Middle Aged; P | 1989 |
Long-term use of valproate in primary psychiatric disorders.
Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combination; F | 1989 |
Antidepressant drug therapy for bulimia: current status.
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method | 1986 |
60 other studies available for valproic acid and Depressive Disorder
| Article | Year |
|---|---|
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series.
Topics: Adult; Agoraphobia; Antibodies, Monoclonal, Humanized; Antidepressive Agents; Antimanic Agents; Benz | 2020 |
Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test.
Topics: Aggression; Agonistic Behavior; Animals; Anxiety; Bipolar Disorder; Carbamazepine; Cycloheptanes; De | 2019 |
Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries.
Topics: Adult; Alopecia; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Austria; Bipolar Dis | 2018 |
Antidepressive effect of sodium valproate involving suppression of corticotropin-releasing factor expression and elevation of BDNF expression in rats exposed to chronic unpredicted stress.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Corticosterone; Corticotropin-Rel | 2014 |
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Benzo | 2013 |
[Pulmonary eosinophilia associated with valproic acid].
Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Anxiety Disorders; Bronchoalveolar Lavage Flu | 2015 |
Upregulating serotonin transporter expression and downregulating monoamine oxidase-A and indoleamine 2, 3-dioxygenase expression involved in the antidepressant effect of sodium valproate in a rat model.
Topics: Animals; Antidepressive Agents; Chronic Disease; Depressive Disorder; Disease Models, Animal; Hippoc | 2014 |
[Hemoperfusion with activated charcoal on valproic acid poisoning. A case report].
Topics: Benzodiazepines; Charcoal; Combined Modality Therapy; Depressive Disorder; Drug Overdose; Female; Fl | 2015 |
Evidence in support of using a neurochemistry approach to identify therapy for both epilepsy and associated depression.
Topics: Animals; Anticonvulsants; Brain; Depression; Depressive Disorder; Disease Models, Animal; Dopamine; | 2016 |
Septo-optic dysplasia and psychiatric disorders: a case report.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Female; Humans; Magnet | 2008 |
Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antimanic Agents; Carbamazepine; Case-Control Studie | 2009 |
Non-life-threatening leukopenia in a renal transplant recipient with acute overdose of mycophenolate mofetil.
Topics: Adult; Antidepressive Agents; Benzodiazepines; Charcoal; Cholestyramine Resin; Depressive Disorder; | 2008 |
Aripiprazole-induced sialorrhea.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disor | 2009 |
[Lactic acidosis after voluntary intoxication with valproic acid].
Topics: Acidosis, Lactic; Acute Kidney Injury; Adult; Combined Modality Therapy; Depressive Disorder; Emerge | 2010 |
Symptoms of agitated depression and/or akathisia.
Topics: Affective Disorders, Psychotic; Akathisia, Drug-Induced; Anticonvulsants; Antidepressive Agents, Sec | 2011 |
Neural correlates of treatment response in depressed bipolar adolescents during emotion processing.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Diso | 2013 |
Charcoal enhancement of treatment for tricyclic-induced mania.
Topics: Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antidotes; Bipolar Disorder; Charcoal; Depres | 2002 |
Lamotrigine use in geriatric patients with bipolar depression.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Dose-Response Rela | 2002 |
Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders.
Topics: Adult; Akathisia, Drug-Induced; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brief Psychiatr | 2003 |
Antidepressant-associated mania with escitalopram.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Citalopram; Depressive Disorder; Humans; Male; Selective S | 2004 |
Fatal hepatic failure and valproate.
Topics: Anticonvulsants; Depressive Disorder; Fatal Outcome; Humans; Liver Failure, Acute; Male; Middle Aged | 2005 |
Drug treatments for bipolar disorder: 1--Acute manic or depressive episodes.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2005 |
Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings.
Topics: Adult; Biomarkers; Bipolar Disorder; Brain; Cohort Studies; Depressive Disorder; Emotions; Female; F | 2006 |
Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate.
Topics: Adolescent; Anticonvulsants; Anxiety Disorders; Cross-Sectional Studies; Depressive Disorder; Female | 2006 |
Reduction of dominant or submissive behaviors as models for antimanic or antidepressant drug testing: technical considerations.
Topics: Animals; Antidepressive Agents; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Data Interpret | 2007 |
Psychiatric manifestations of temporal lobe epilepsy in older adults.
Topics: Aged; Dementia; Depressive Disorder; Diagnosis, Differential; Electroencephalography; Epilepsy, Temp | 1995 |
Valproic toxicity with fluoxetine therapy.
Topics: Adolescent; Age of Onset; Depressive Disorder; Dose-Response Relationship, Drug; Epilepsy, Generaliz | 1995 |
Lithium: the present and the future.
Topics: Acute Disease; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Interactions; Female; Huma | 1995 |
Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk.
Topics: Adolescent; Adult; Anemia; Carbamazepine; Depressive Disorder; Desipramine; Drug Therapy, Combinatio | 1995 |
Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients.
Topics: Adult; Alcoholism; Bipolar Disorder; Comorbidity; Depressive Disorder; Dose-Response Relationship, D | 1994 |
Divalproex sodium in the treatment of refractory affective disorders.
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; Female | 1993 |
Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs.
Topics: Affect; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Depressive | 1995 |
The use of valproate in an elderly population with affective symptoms.
Topics: Affective Disorders, Psychotic; Age Factors; Aged; Antimanic Agents; Comorbidity; Depressive Disorde | 1996 |
Status epilepticus associated with the combination of valproic acid and clomipramine.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Tricyclic; Clomipramine; Depressive Disorder; Female; | 1997 |
Combined valproate or carbamazepine and electroconvulsive therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 1997 |
Carnitine for valproic acid-induced hyperammonemia.
Topics: Adult; Ammonia; Bipolar Disorder; Carbamoyl-Phosphate Synthase (Ammonia); Carnitine; Depressive Diso | 1997 |
An open study of lamotrigine in refractory bipolar depression.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Cohort Studies; Depress | 1997 |
Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy.
Topics: Adolescent; Adult; Affect; Aged; Agoraphobia; Anxiety Disorders; Bipolar Disorder; Cognitive Behavio | 1998 |
Interaction of fluoxetine and valproic acid.
Topics: Adult; Comorbidity; Cytochrome P-450 Enzyme System; Depressive Disorder; Drug Interactions; Female; | 1998 |
Classic mania: treatment response to divalproex or lithium.
Topics: Bipolar Disorder; Depressive Disorder; Humans; Lithium; Psychiatric Status Rating Scales; Randomized | 1998 |
Decrease of valproic acid concentration in the blood when coprescribed with fluoxetine.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Agents, Second-Generation; Depressive Disor | 1997 |
Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment.
Topics: Aged; Bipolar Disorder; Depressive Disorder; Functional Laterality; Human Growth Hormone; Humans; Ma | 2000 |
Periodic motor impairments in a case of 48-hour bipolar ultrarapid cycling before and under treatment with valproate.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Handwriting; Humans; Male; Movement D | 2000 |
'That is funny.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; | 2000 |
Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antimanic Agents; Bipolar Disorder; Carbamazepine; De | 2001 |
Introduction: the role of anticonvulsants as mood stabilizers.
Topics: Anticonvulsants; Bipolar Disorder; Depressive Disorder; Humans; Lamotrigine; Lithium; Terminology as | 2001 |
Consensus guidelines outline drug selection and sequencing options for bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cyclohexanols; Depr | 2000 |
Nonadherence with mood stabilizers: prevalence and predictors.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Attitude of Health Personnel; Attitude to Health; Bip | 2002 |
[Duration of antidepressive treatments].
Topics: Antidepressive Agents, Tricyclic; Bupropion; Carbamazepine; Depressive Disorder; Dose-Response Relat | 1992 |
Alopecia and mood stabilizers: two case reports.
Topics: Adult; Alopecia; Carbamazepine; Clorazepate Dipotassium; Depressive Disorder; Female; Fluvoxamine; H | 1992 |
Sodium valproate augmentation of fluoxetine or fluvoxamine effects.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxa | 1992 |
Sodium valproate as an antidepressant.
Topics: Adult; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder; Electroconvulsive Ther | 1992 |
Valproate for rapid-cycling unipolar affective disorder.
Topics: Adult; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Lithium; Longitudinal Studies | 1991 |
Selective response to carbamazepine in a case of organic mood disorder.
Topics: Aged; Carbamazepine; Depressive Disorder; Female; Humans; Neurocognitive Disorders; Phenobarbital; P | 1990 |
Sleep disorders and depression with atypical features: response to valproate.
Topics: Adult; Depressive Disorder; Electroencephalography; Epilepsies, Partial; Female; Humans; Male; Neuro | 1989 |
New developments in long-term preventive therapy.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Diethylcarbamazine; Dose-Response Rela | 1986 |
The effect of sodium valproate on serum cortisol levels in healthy subjects and depressed patients.
Topics: Adult; Depressive Disorder; Dexamethasone; Female; Humans; Hydrocortisone; Male; Middle Aged; Valpro | 1988 |
[Personal experience with the prophylactic effect of dipropylacetamide].
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; Humans; Male; Middle Aged; Psychotic Disorders | 1988 |
Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients.
Topics: Adult; Amitriptyline; Anticonvulsants; Depressive Disorder; Drug Therapy, Combination; Female; Human | 1988 |
[New developments in preventive therapy of manic-depressive disease].
Topics: Antidepressive Agents; Carbamazepine; Depressive Disorder; Dose-Response Relationship, Drug; Humans; | 1988 |